Why the study?
Does pediatric allogeneic hematopoietic cell transplantation increase the risk of late cardiovascular morbidity and mortality compared to the general population?
Does pediatric allogeneic hematopoietic cell transplantation increase the risk of late cardiovascular morbidity and mortality compared to the general population?
Answers are grounded in this paper and cite their sources.
Childhood cancer and hematopoietic cell transplantation survivors face a significantly higher risk of early cardiovascular disease and mortality compared to the general population.
Early cardiovascular disease is relatively common among childhood cancer survivors (CCS). A high risk of accelerated atherosclerosis and a 8.2-fold higher cardiac mortality rate have been reported (1). Arterial stiffness, an independent risk factor for cardiovascular morbidity and mortality in adults, seems to increase in young adult CCS (2). In hematopoietic cell transplantation (HCT) survivors, the risk of cardiovascular death is 24 fold higher than the general population, and cardiovascular adverse events occur earlier than average (3).
No takes yet. Share an insight, caveat, or question.
CN et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: